Design and Population of the VALOR-CKD Study: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating the Efficacy and Safety of Veverimer in Slowing Progression of Chronic Kidney Disease in Patients with Metabolic Acidosis.

Vandana S MathurDavid A BushinskyLesley InkerGerrit KlaernerElizabeth LiDawn ParsellVlado PerkovicYuri StasivMichael WalkerDonald E WessonDavid C WheelerNavdeep Tangri

Published in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2022)

VALOR-CKD has recruited a large population of people with metabolic acidosis at high risk for CKD progression to determine the effects of veverimer on the risk of progressive loss of kidney function.

Keyphrases

double blind
chronic kidney disease
placebo controlled
end stage renal disease
clinical trial
phase iii
phase ii
study protocol
multiple sclerosis
randomized controlled trial
open label
cross sectional